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Abstract 
The present article describes the preparation of beta emitter lutetium-177-lebeled zirconia 
colloid and its preliminary physico-chemical and biological evaluation of suitability for local 
radionuclide therapy. 
The new 177Lu-labeled therapeutic radiopharmaceutical candidate was based on the synthesis 
mode of a previously described zirconia nanoparticle system. Morphology and size of 
developed radiopharmaceutical compound were evaluated through scanning electron 
microscope and dynamic light scattering methods. The radiocolloid had a 1.7 micrometer 
mean diameter and showed suitable radiolabeling and colloid size in vitro stability at RT and 
during blood sera stability test. After the in vitro characterizations, the product was 
investigated in the course of the treatment of a spontaneously diseased dog veterinary 
patient’s hock joint completed with SPECT imaging follow-up measurements and a dual-
isotope SPECT imaging tests with conventional 99mTc-MDP bone scintigraphy. In the treated 
dog any clinical side effects or signs of histopatological alterations of the joints could not be 
observed during the treatment. SPECT follow-up studies unequivocally showed appropriately 
high localization of the 177Lu-labeled colloid in hock joint and detectable but negligible 
radiocolloid leakages in the nearest lymph node, respectively. 
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On the basis of biological follow-up tests orthopaedic team assumed that the 177Lu-labeled 
zirconia colloid based local radionuclide therapy resulted in a significant and long-term 
improvement in clinical signs of the patient without any remarkable side effects. 
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Introduction 
Localized irradiation of the synovial lining of a joint has emerged as one of the most successful 
modality for the treatment of rheumatoid arthritis [1]. Local radiation therapy can be effected 
by intraarticular administration of suitable beta-emitting radionuclides which are bound to 
colloidal size range particles. This treatment is known as radiosynovectomy (RS) or 
radiosynoviorthesis (RSV). Numerous beta-emitting (usually lanthanide) radioisotope was used 
for RSV purpose such as 90Y, 153Sm, 188Re, 165Dy, 166Ho, 169Er and 170Tm [2-6]. We report here the 
first trials of 177Lu isotope [T1/2=6.73 d, Eβ(max)=0.49 MeV, Eγ=208 keV (11%)] labeled zirconia 
based colloid particles: their preliminary physico-chemical and biological evaluation for 
suitability as a new potential therapeutic agent candidate for radiation synovectomy. 
Zirconia, a ceramic material is used for the synthesis of nanoparticle systems [7, 8] and for 
other biomedical applications e.g. in dental implants [9]. It is known to be biocompatible [10, 
11], and our preliminary experiments have shown that zirconia is also biodegradable under 
certain circumstances [12]. Zirconia crystal lattice is known to host yttrium or other lanthanide 
ions via replacement of Zr4+ ions to Y3+ or Ln3+ ions. This phenomenon is used widely to 
stabilize monoclinic crystal structure of zirconia during sintering procedures and therefore this 
characteristics makes zirconia based colloid system suitable for viable binding and carrying of 
the radiolanthanide 177Lu for the intraarticular injection of therapeutic dose to the joints, as 
well. 
Besides biocompatibility and biodegradability, the most important attributes of radionuclide 
carrier colloids, microparticulates focusing as the carrier of radionuclides for intra-arterial 
therapy are appropriate particle size distribution and high radiochemical stability to overcome 
the possible in vivo leaching of the radioisotope [13]. In the present study, we have explored 
the possibility of a zirconia particulate system above one micrometer effective mean particle 
size. 
In this present study the new product was investigated in the course of the radionuclide 
therapy of a spontaneously diseased dog veterinary patient’s hock joint. As previously, the 
objective of treatment of a veterinary patient was to provide a preliminary preclinical proof of 
concept of a potential prospective human medical application and pharmaceutical before the 
further detailed evaluations [12, 14, 15]. 
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Materials and methods 
Chemicals 
177Lu isotope (radiochemical purity > 99.9%) was obtained from the Radioisotope Centre 
Polatom, Poland in the form of 0.04 M HCl solution of lutetium chloride (LuCl3). For the control 
examination, lyophilized MDP kit was obtained from Medi-Radiophamra Co. Ltd., Hungary. 
Absolute ethanol (a.r., >99.7%, < 0.2% water, Reanal), cesium chloride (CsCl, Specpure, trace 
metal basis); zirconium(IV) butoxide (TBOZ, 80 wt% in butanol, Sigma-Aldrich) were used for 
ZrO2 synthesis. TBOZ was kept and manipulated under argon gas. Ultrapure water was 
collected from a MilliQ System. HEPES buffer solution (1M, 59205C) was purchased from 
Sigma-Aldrich. 
Preparation of 177Lu-labeled zirconia particles 
The 177Lu-labeled colloid was based on previously prepared and described zirconia nanoparticle 
system [16, 17]. Briefly, 100 ml of abs. ethanol was stirred at 300 rpm and heated to 60°C in a 
closed glove box flushed with argon gas. 0.4 ml of freshly prepared 0.1 M CsCl solution was 
pipetted into the ethanol. After homogenization 3.25 ml of TBOZ was quickly added to it and 
the glass vial was closed. The solution became white within one minute. The sol was 
centrifuged three times at 4000 rpm (10 min). The supernatant was separated and the 
sediment was resuspended in ethanol by an ultrasonic homogenizer (150VT, BioLogics). The 
obtained ZrO2 sol was dried at 60°C and stored in powder form. Before the radiolabeling, 0.1 
mg of it was resuspended in 300 µl 0.01 M HEPES buffer (pH 7.0) and ultrasonicated for 30 
min. Then 5 µl of 177LuCl3 in 0.04M HCl (activity: 316 MBq) and 50 µl 0.1 M HEPES buffer was 
added to the resuspended colloid and the 177Lu containing colloid suspension was incubated at 
RT for 15 minutes. 
In vitro characterization of labeled zirconia particles 
To evaluate its in vitro stability, 177Lu-labeled zirconia colloid was kept at 21°C up to 1 week 
after the preparation and particle size distribution and 177Lu-labeling yield were investigated 
after 1, 8, 24 and 168 hours. Labelling efficiency was examined by thin layer chromatography 
(ITLC-SG, silica gel impregnated glass fiber plates, Gelman Sciences Inc). In vitro serum stability 
was evaluated in canine blood serum. A 20-µL aliquot of radiolabeled product was added to 
500 µL of serum. Sample was stored at 37°C and radioabeling yield was evaluated at 1, 8, 24 
and 168 hours of incubation using the same ITLC-SG method. 
1 7 7
L u - l a b e l e d  z i r c o n i a  p a r t i c l e s  f o r  r a d i o s y n o v e c t o m y  
 
5 / 12 
 
Morphological investigation of the zirconia particles was carried out on a ZEISS EVO 40XVP 
scanning electron microscope (SEM, tungsten cathode, 20 kV accelerating voltage). Diluted 
sample of the original zirconia sol was dropped and dried on carbon coated copper grids. 
Particle size distribution measurements were carried out in an Avid Nano w310i dynamic light 
scattering (DLS) instrument equipped with a fiber coupled laser diode (λ = 660 nm) and a 
silicon avalanche photodiode detector at fixed angle of 90°. Input parameters were: solvent 
refractive index: 1.330, viscosity: 0.891 Pas, temperature: 25°C, laser power: 25%, optical 
attenuation: 3%. 10 runs of 10 seconds were recorded. The number weighted size distribution 
function is presented. The suspension was ultrasonicated for 5 min before the measurement. 
Biological evaluation of prepared compound 
An eleven-year old spayed Cavalier King Charles Spaniel was referred into our Institute with 
chronic, destructive, therapy-resistant osteoarthritis in the left hock joint. The dog had been 
walking 3-legged for 6 months, and the handling ortopaedic veterinary-team offered 
amputation to the owners. The patient’s blood tests showed increased white cell number (19.6  
G/l) with lymphocytosis (5.0 G/l) and elevated CRP (C-reactive protein: 28 mg/l) and ALP 
(alkaline phosphatase: 613 IU/l) levels. These latter findings and the physical examinations 
revealed painful, swelling hock joint and atrophic muscles in the left hind-leg. 
The radionuclide therapy was performed by injecting 200 µl of radiolabeled compound 
intraarticularly directly to the left hock joint of the dog. The 178 MBq injected activity was 
selected by the extrapolation from the human related EANM procedure guidelines [18]. After 
intraarticular application of compound the hock joint was immobilized with a bandage, and the 
animal was taken into a cage for 3 days and only short walks were allowed for her. Bandage 
and the overall physical conditions (and joint flexibility) were checked twice daily. 
Serial whole body SPECT (“single-photon emission computed tomography”) images were made 
by AnyScan SPECT camera (Mediso Inc. HU) 1, 8, 24 hours and 1 week, 1 month and 3 months 
post administration to detect the potential leakage of activity from the hock joint and so the 
potential degradation of the colloidal product before the proper time. 24 hours, 1 week and 1 
month post-injection control SPECT examination was performed by dual-isotope SPECT 
imaging: before the SPECT investigations 99mTc-MDP (“Methanediphosphonic acid, Medronic 
acid”) injection (Medi-Radiopharma Co. Ltd., Hungary) was applied intravenously in the patient 
and the localizations and biodistributions of the two radiopharmaceuticals were recorded 
simultaneously. Resulted SPECT/CT images were processed by ROI / VOI (“region of interest”, 
“volume of interest”) analysis using Interview Software (Mediso Ltd. Hungary). 
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Besides the SPECT imaging follow-up, serial blood and urine samples were collected and 
analyzed to detect potential excretion ratio of injected radioactivity through these pathways. 
1, 3 days, 1,2,4 weeks and 3 months post-treatment blood samples were also collected for 
carrying out haematological, biochemical and Comet assay studies to check the possible 
radiotoxicological effects. (Haem. parameters studied: WBC, RBC, nemoglobin, hematocrit 
(PCV), MCV, MCH, MCHC, platelets, neutrophils, lymphocytes, eosinophils, monocytes, 
basophils; Biochem. parameters studied: AST, ALT, ALP, total bilirubin, total prot, alb, glob, alfa 
amilase, glu, chol, urea, creatinine, P, Na, K, Cl, Ca.) 
The treated animal was kept in compliance with all applicable sections of the Hungarian Laws 
No. XXVIII/1998 and LXVII/2002 on the protection and welfare of animals and animal welfare 
directions and regulations of the European Union. The study was also approved by the 
Governmental Ethical Committee (permission No. 22.1/609/001/2010). The informed owners 
of the only referred dog patient declared their consent to the study. 
 
Results and Discussion 
In vitro characterization results 
Morphology and particle size distribution of the product were examined through SEM and DLS 
and it could be concluded that zirconia particles, which were originally nearly 380 nm of 
diameter [17] were partially dispersed in HEPES buffer, and by this means we could obtain 
loosely packed inorganic aggregates (Fig 1). Over micron size aggregates remain in the slurry 
with a mean diameter of 1.7 micrometer according to the DLS size distribution function (Fig 
2).The resulted aggregates possessed higher surface area (16 m2/g) [17] and lower solid 
content than single zirconia particles of the same diameter (specific surface area 11 m2/g) 
[16]. The advantage of such a construction against compact particles of micron-sized diameter 
is: lower quantity of extraneous material applied regarding to larger-colloid surface area for 
the grafting of 177Lu radionuclides (higher drug/carrier dose). The lower solid content may be 
of interest for the long-term degradation and elimination of the carrier colloid, as well. 
The radiolabeled colloid showed high in vitro radiochemical and colloid size stability. The 
labeling efficiency of the sample incubated at room temperature was found to be above 99% 
after 1, 8 and 24 hours and 97% after 1 week of storage. 177Lu-labeled particles had durable 
blood serum stability during the 1-week incubation. The 177Lu-bearing yield was found to be 
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>99% after 1, 8, and 24 hours and 98% 1 week postlabeling. DLS measurements proved that 
the storage at RT did not cause significant change in particle size distributions. The mean 
hydrodynamic diameter values of the colloidal product were found in the range of 1.4–2.5 µm 
during the 1-week follow-up. Results suggested that 177Lu-labeled zirconia particles do not 
disintegrate under the effect of self-beta-radiation or by the storing in different physiological 
conditions at different temperatures. 
Results of biological study 
In the treated dog no clinical side effects were recorded during the treatment. The SPECT 
images were recorded at 1, 8, 24 hours and 1 week, 1 month and 3 months post-
administration time points. SPECT follow-up studies unequivocally proved the localization of 
the 177Lu-labeled particles in the hock joint as well as negligible leakages (under 1 % of total 
injected activity was measured by ROI/VOI analyses) of the radiocolloid in the nearest lymph 
node. Figure 3 and Figure 4 represent dorsoventral dual-isotope SPECT images of the 
veterinary patient recorded simultaneously 24 hours and 1 month post-administration using 
99mTc-MDP as control radiopharmaceutical. Images “A” of Fig 3 and Fig 4 show the only 
detectable source of the 177Lu in the whole body SPECT scans, while images “B” show parallel 
recorded whole body 99mTc-MDP distributions. The exact localization the hock joint is signed by 
retrospectively added reference lines in the paired scans. Investigations of blood and urine 
samples have confirmed the lack of leakage of the radiocolloid, also only insignificant ratios of 
activity (under 0.01 % values of total ID) were found in the collected samples. Moreover, no 
remarkable differences could be perceived in haematological and biochemical parameters as 
well as in Comet assays before and after the application. All these biological evaluation 
indicates that the 177Lu-labeled zirconia colloid had no adverse effects and thus might be 
acceptable for further evaluation. 
Three days after treatment bandage was removed and the patient was agitated progressively 
to move. One week to 3 months after completion of treatment there was a significant 
improvement in clinical symptoms eg.: the dog could walk hours with only a little lame, no 
swelling, joint flexibility as in contra lateral hock joint. Follow-up bone scintigrams 1 month and 
3 months post-treatment revealed normal 99mTc-MDP radiopharmaceutical uptakes (see fig 4 
image “B” and fig 5). On the basis of follow-up tests and owner’s semi-quantitative evaluations 
orthopaedic team assumed that local 177Lu-labeled zirconia colloid based radionuclide therapy 
resulted a significant and long-term improvement in clinical signs without any remarkable side 
effects. 
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Conclusions 
The aims of our experiments were to produce a novel 177Lu-bearing therapeutic 
radiopharmaceutical candidate using biocompatible, inorganic carrier colloid, which may 
function as a potential alternative to other radiocolloidal agents applied in radiation 
synovectomy at present. The 177Lu-labeled colloid was prepared following a simple 
radiolabeling method of a previously originated zirconia nanoparticle system. The new agent 
was had excellent in vitro 177Lu-bearing and colloidal stability. The product was investigated in 
the course of treatment of a spontaneously diseased dog veterinary patient. In vivo studies 
also proved good stability of the product by the clearly visible and detectable high ratio of 
retained activity in the treated hock joint during the one week follow-up. The present 
preliminary findings showed the potential of the novel product towards its application as an 
alternative compound for radiation synovectomy. 
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Figure 1. SEM images of 177Lu labeled zirconia colloid: partially packed nanoparticular 




Figure 2. The resulted effective particle size distribution of 177Lu labeled zirconia colloid: mean 
diameter MD=1.7 µm 
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Figure 3. Dual isotope SPECT images of dog veterinary patient. A: 177Lu labeled zirconia colloid 
injected intraarticularly into the left hock joint, 24 hour post injection; B: control 99mTc-MDP 
radiopharmaceutical injected i.v. 1 hour post injection 
1 7 7
L u - l a b e l e d  z i r c o n i a  p a r t i c l e s  f o r  r a d i o s y n o v e c t o m y  
 
12 / 12 
 
 
Figure 4. Dual isotope SPECT images of dog veterinary patient. A: 177Lu labeled zirconia colloid 
injected intraarticularly into the left hock joint, 1 month post injection; B: control 99mTc-MDP 
radiopharmaceutical injected i.v. 1 hour post injection 
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Figure 5. 99mTc-MDP whole body SPECT scan of dog veterinary patient 3 months post 
treatment.  
 
 
